元医生智能体/内分泌/知识库
文献速递

骨密度作为骨质疏松试验替代终点的作者回复

[Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials – Author's reply
RSS 订阅 · The Lancet Diabetes and Endocrinology

作者回应Eastell等人对其观点文章的评论，澄清该观点并非针对SABRE协作本身，而是针对目标导向骨质疏松治疗工作组对其结果的使用。作者认可SABRE研究是骨研究领域的重要里程碑，并指出SABRE作者证明了研究中骨密度变化与抗骨折疗效之间的关系，从而确定了预测骨折预防的骨密度变化阈值。

要点

  • 作者观点针对目标导向治疗工作组对SABRE结果的使用方式，而非SABRE本身
  • SABRE研究显示骨密度变化与抗骨折疗效相关，并确定了预测骨折预防的阈值

核心结论

  • 作者的回复澄清其观点文章并非针对SABRE协作，而是针对目标导向骨质疏松治疗工作组对该协作结果的使用

主要发现

  • SABRE协作是一项骨研究领域的里程碑工作，已获广泛认可，包括作者的认可
  • SABRE作者证明了研究中骨密度变化与抗骨折疗效之间的关系

关键数值与推荐

  • SABRE研究确定了预测骨折预防的骨密度变化阈值

临床怎么用

  • 临床中应区分SABRE的研究发现与其在目标导向治疗工作组中的实际应用，避免过度解读

以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。

原文

I thank Richard Eastell and colleagues for their Correspondence regarding my Viewpoint1 on the use of bone mineral density (BMD) targets in goal-directed osteoporosis treatment. The work of their SABRE collaboration is a major milestone in bone research which has been widely acknowledged, including by me.2 My Viewpoint was not on SABRE, but on the use to which its findings have been put by the Taskforce on Goal-Directed Osteoporosis Treatment.3 The SABRE authors demonstrated a relationship between BMD changes in studies and findings of anti-fracture efficacy in those studies, such that a threshold in BMD change that predicted fracture prevention was identified.

来源：The Lancet Diabetes and Endocrinology，查看原文。版权归原作者所有。

引用

  1. The Lancet Diabetes and Endocrinology：[Correspondence] Bone mineral density as a surrogate endpoint in osteoporosis trials – Author's reply
在智能体中追问阅读原文 ↗

供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。